Age-specific immunoglobulin G (IgG) and IgA to pneumococcal protein antigens in a population in coastal Kenya

被引:36
作者
Laine, C
Mwangi, T
Thompson, CM
Obiero, J
Lipsitch, M
Scott, JAG
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] KEMRI, Ctr Geog Med Res, Wellcome Trust, Kilifi, Kenya
[3] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
基金
英国惠康基金;
关键词
D O I
10.1128/IAI.72.6.3331-3335.2004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Streptococcus pneumoniae is the primary etiological agent of community-acquired pneumonia and a major cause of meningitis and bacteremia. Three conserved pneumococcal proteins-pneumolysin, pneumococcal surface adhesin A (PsaA), and pneumococcal surface protein A (PspA)-are currently being investigated as vaccine candidates. Such protein-based vaccines, if proven effective, could provide a cheaper alternative to conjugate vaccine formulae. Few data from sub-Saharan Africa exist concerning the development of natural antibody to these antigens, however. To investigate the age-specific development of antiprotein immunoglobulin G (IgG) and IgA antibody responses, the sera of 220 persons 2 weeks to 84 years of age from coastal Kenya were assayed using enzyme-linked immunosorbent assays. IgG and IgA antibody responses to each antigen were observed in all age groups. Serum concentrations of IgG and IgA antibody responses to PspA and PdB (a recombinant toxoid derivative of pneumolysin), but not to PsaA, increased significantly with age (P < 0.001). No decline was observed in the sera of the elderly. Anti-protein IgG concentrations were only weakly correlated (0.30 < r < 0.56; P < 0.0001), as were IgA concentrations (0.24 < r < 0.54; P < 0.0001).
引用
收藏
页码:3331 / 3335
页数:5
相关论文
共 27 条
[1]   IMPAIRED NATURAL IMMUNITY TO PNEUMOLYSIN DURING HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES AND AFRICA [J].
AHDAHL, BM ;
RUBINS, JB ;
DALEY, CL ;
GILKS, CF ;
HOPEWELL, PC ;
JANOFF, EN .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (06) :2000-2004
[2]  
Austrian R, 1976, Trans Assoc Am Physicians, V89, P184
[3]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[4]   The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae [J].
Briles, DE ;
Hollingshead, SK ;
Nabors, GS ;
Paton, JC ;
Brooks-Walter, A .
VACCINE, 2000, 19 :S87-S95
[5]   Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA [J].
Briles, DE ;
Hollingshead, SK ;
King, J ;
Swift, A ;
Braun, PA ;
Park, MK ;
Ferguson, LM ;
Nahm, MH ;
Nabors, GS .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (06) :1694-1701
[6]   The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known [J].
Fedson, DS ;
Anthony, J ;
Scott, G .
VACCINE, 1999, 17 :S11-S18
[7]  
Gordon SB, 2003, EMERG INFECT DIS, V9, P747
[8]   The epidemiology of pneumococcal infection in children in the developing world [J].
Greenwood, B .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1999, 354 (1384) :777-785
[9]   Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I [J].
Hausdorff, WP ;
Bryant, J ;
Paradiso, PR ;
Siber, GR .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :100-121
[10]  
HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55